Press Resease

Peptide and Anticoagulant Drugs Market by Type (Antifungal, Hormonal, Ace Inhibitors, Antibiotic, and Other Drugs), by Low Molecular Weight Heparin Type (Heparin Sodium, Enoxaparin Sodium, Dalteparin Sodium, and Fondaparinux), and by Application (Infectious Diseases, Gynecology, Cancer, Diabetes, Cardiology, Osteoporosis, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 09-Aug-2019 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3130 Status : Published

Global peptide and anticoagulant drugs market expected to generate around USD 1,860 million by 2025, at a CAGR of around 4.6% between 2019 and 2025. Anticoagulants drugs are referred to as blood thinners. It is a form of chemical substance that prevents the delay in clotting time and helps to keep the affected area unclotted for a longer time period.

Description

The report covers a forecast and an analysis of the peptide and anticoagulant drugs market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes the drivers and restraints of the peptide and anticoagulant drugs market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the peptide and anticoagulant drugs market on a global and regional level.

In order to give the users of this report a comprehensive view of the peptide and anticoagulant drugs market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Peptide and Anticoagulant Drugs Market

The report provides company market share analysis to give a broader overview of the key players in the peptide and anticoagulant drugs market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the peptide and anticoagulant drugs market on a global and regional basis.

The study provides a decisive view of the peptide and anticoagulant drugs market by segmenting it based on type, low molecular weight heparin type, application, and region. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some key players operating in the peptide and anticoagulant drugs market are Sun Pharmaceutical Industries, Baxter, HemmoPharma, Celsus, Wockhardt, AmbioPharm, Biofer, Bachem, Pfizer, Abbott Laboratories, Aspen, Eli Lilly, Takeda, Teva, Sanofi, and Novo Nordisk.

This report segments the global peptide and anticoagulant drugs market into:

Global Peptide and Anticoagulant Drugs Market: By Type

  • Antifungal
  • Hormonal
  • Ace Inhibitors
  • Antibiotic
  • Other Drugs

Global Peptide and Anticoagulant Drugs Market: By Low Molecular Weight Heparin Type

  • Heparin Sodium
  • Enoxaparin Sodium
  • Dalteparin Sodium
  • Fondaparinux

Global Peptide and Anticoagulant Drugs Market: By Application

  • Infectious Diseases
  • Gynecology
  • Cancer
  • Diabetes
  • Cardiology
  • Osteoporosis
  • Others

Global Peptide and Anticoagulant Drugs Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Peptide and Anticoagulant Drugs Market Revenue, 2016-2025 (USD Million)
    • 2.2. Global Peptide and Anticoagulant Drugs Market: Snapshot
  •  
  • Chapter 3. Peptide and Anticoagulant Drugs Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Peptide and Anticoagulant Drugs Market Drivers: Impact Analysis
      • 3.2.2. Increasing prevalence of chronic diseases
      • 3.2.3. Rising population
      • 3.2.4. Government support
      • 3.2.5. Increasing healthcare expenditure
    • 3.3. Market restraints
      • 3.3.1. Availability of alternative drugs
    • 3.4. Opportunities
      • 3.4.1. Emerging markets
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Type
      • 3.6.2. Market attractiveness analysis, by Low molecular Heparin weight type
      • 3.6.3. Market attractiveness analysis, by Application
      • 3.6.4. Market attractiveness analysis, by Region
  •  
  • Chapter 4. Global Peptide and Anticoagulant Drugs Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Peptide and Anticoagulant Drugs Market: Company Market Share, 2018
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
      • 4.2.4. Research and Development and Regional Expansion
  •  
  • Chapter 5. Global Peptide and Anticoagulant Drugs Market - Type Analysis
    • 5.1. Global Peptide and Anticoagulant Drugs Market: type overview
      • 5.1.1. Global Peptide and Anticoagulant Drugs Market Share, by type, 2018 and 2025
    • 5.2. Antifungal
      • 5.2.1. Global Peptide and Anticoagulant Drugs Market for Antifungal, 2016-2025 (USD Million)
    • 5.3. Hormonal
      • 5.3.1. Global Peptide and Anticoagulant Drugs Market for hormonal, 2016-2025 (USD Million)
    • 5.4. Ace inhibitors
      • 5.4.1. Global Peptide and Anticoagulant Drugs Market for Ace inhibitors, 2016-2025 (USD Million)
    • 5.5. Antibiotic
      • 5.5.1. Global Peptide and Anticoagulant Drugs Market for Antibiotic, 2016-2025 (USD Million)
    • 5.6. Other drugs
      • 5.6.1. Global Peptide and Anticoagulant Drugs Market for Other drugs, 2016-2025 (USD Million)
  •  
  • Chapter 6. Global Peptide and Anticoagulant Drugs Market - Low Molecular Heparin Type Analysis
    • 6.1. Global Peptide and Anticoagulant Drugs Market: Low molecular Heparin type overview
      • 6.1.1. Global Peptide and Anticoagulant drugs Market Share, by Low molecular Heparin type, 2018 and 2025
    • 6.2. Heparin sodium
      • 6.2.1. Global Peptide and Anticoagulant Drugs Market for Heparin sodium, 2016-2025 (USD Million)
    • 6.3. Enoxaparin Sodium
      • 6.3.1. Global Peptide and Anticoagulant Drugs Market for Enoxaparin sodium, 2016-2025 (USD Million)
    • 6.4. Dalteparin Sodium
      • 6.4.1. Global Peptide and Anticoagulant Drugs Market for Dalteparin Sodium, 2016-2025 (USD Million)
    • 6.5. Fondaparinux
      • 6.5.1. Global Peptide and Anticoagulant Drugs Market for Fondaparinux, 2016-2025 (USD Million)
  •  
  • Chapter 7. Global Peptide and Anticoagulant Drugs Market - Application Analysis
    • 7.1. Global Peptide and Anticoagulant Drugs Market: Application overview
      • 7.1.1. Global Peptide and Anticoagulant Drugs Market Share, by Application, 2018 and 2025
    • 7.2. Infectious disease
      • 7.2.1. Global Peptide and Anticoagulant Drugs Market for infectious disease, 2016-2025 (USD Million)
    • 7.3. Gynecology
      • 7.3.1. Global Peptide and Anticoagulant Drugs Market for gynecology, 2016-2025 (USD Million)
    • 7.4. Cancer
      • 7.4.1. Global Peptide and Anticoagulant Drugs Market for cancer, 2016-2025 (USD Million)
    • 7.5. Diabetes
      • 7.5.1. Global Peptide and Anticoagulant Drugs Market for diabetes, 2016-2025 (USD Million)
    • 7.6. Cardiology
      • 7.6.1. Global Peptide and Anticoagulant Drugs Market for cardiology, 2016-2025 (USD Million)
    • 7.7. osteoporosis
      • 7.7.1. Global Peptide and Anticoagulant Drugs Market for osteoporosis 2016-2025 (USD Million)
    • 7.8. Others
      • 7.8.1. Global Peptide and Anticoagulant Drugs Market for Others, 2016-2025 (USD Million)
  •  
  • Chapter 8. Global Peptide and Anticoagulant Drugs Market - Regional Analysis
    • 8.1. Global Peptide and Anticoagulant drugs Market: Regional overview
      • 8.1.1. Global Peptide and Anticoagulant drugs Market Share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
      • 8.2.2. North America Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
      • 8.2.3. North America Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.2.4.2. The U.S. Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.2.4.3. The U.S. Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.2.5. Rest of North America
        • 8.2.5.1. Rest of North America Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.2.5.2. Rest of North America Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.2.5.3. Rest of North America Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
    • 8.3. Europe
      • 8.3.1. Europe Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
      • 8.3.2. Europe Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
      • 8.3.3. Europe Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.3.4. Germany
        • 8.3.4.1. Germany Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.3.4.2. Germany Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.3.4.3. Germany Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.3.5. U.K.
        • 8.3.5.1. U.K. Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.3.5.2. U.K. Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.3.5.3. U.K. Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.3.6.2. France Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.3.6.3. France Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.3.7. Rest of Europe
        • 8.3.7.1. Rest
        • of Europe Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.3.7.2. Rest of Europe Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.3.7.3. Rest
        • of Europe Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
      • 8.4.2. Asia Pacific Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
      • 8.4.3. Asia Pacific Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.4.4. China
        • 8.4.4.1. China Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.4.4.2. China Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.4.4.3. China Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.4.5.2. Japan Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.4.5.3. Japan Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.4.6. India
        • 8.4.6.1. India Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.4.6.2. India Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.4.6.3. India Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.4.7. Rest of Asia Pacific
        • 8.4.7.1. Rest of Asia Pacific Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.4.7.2. Rest of Asia Pacific Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.4.7.3. Rest of Asia Pacific Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
      • 8.5.2. Latin America Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
      • 8.5.3. Latin America Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.5.4.2. Brazil Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.5.4.3. Brazil Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
        • 8.5.5.2. Rest of Latin America Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
        • 8.5.5.3. Rest of Latin America Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Peptide and Anticoagulant Drugs Market Revenue, by type, 2016-2025 (USD Million)
      • 8.6.2. The Middle East and Africa Peptide and Anticoagulant Drugs Market Revenue, by low molecular Heparin type, 2016-2025 (USD Million)
      • 8.6.3. The Middle East and Africa Peptide and Anticoagulant Drugs Market Revenue, by Application, 2016-2025 (USD Million)
  •  
  • Chapter 9. Company Profile
    • 9.1. Sun Pharmaceutical Industries
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product Portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. Baxter
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product Portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. HemmoPharma
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product Portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Celsus
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product Portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. AmbioPharm
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product Portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. Bachem
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product Portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. Pfizer
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product Portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Abbott Laboratories
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product Portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. Aspen
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product Portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Takeda
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Product Portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments

Methodology

Free Analysis

Peptide drugs are drugs that act as hormones. These molecules are universally called proteins and carry a long chain of amino acids, whose key functions are recognized on the basis of amino acid size and sequence. These drugs are used at a larger scale in treating various diseases, such as cancer, diabetes, pathology, cardiovascular, and coagulation disorders. Anticoagulants drugs are referred to as blood thinners. It is a form of chemical substance that prevents the delay in clotting time and helps to keep the affected area unclotted for a longer time period. These drugs are specially used for treating diseases like pulmonary embolism, deep vein thrombosis, stroke, myocardial infarction, and others. In combination, both peptide and anticoagulant drugs have a wide range of applications that play an important role in terms of providing treatment for several diseases like cardiovascular, osteoporosis, cancer, diabetes, and coagulation disorders.

The global peptide and anticoagulant drugs market is likely to showcase significant growth in the future, due to the increasing prevalence of chronic diseases like cancer, osteoporosis, diabetes, and coagulation disorders, growing healthcare expenditure, rising global population, and increasing number of government initiatives to support pharmaceutical companies. The growing awareness among individuals about the benefits of early tests is also contributing toward the expansion of the peptide and anticoagulant drugs market globally. Additionally, pricing and regulatory issues and high degrees of consolidation are also propelling the peptide and anticoagulant drugs market. However, the availability of alternative drugs may be a major restraint in the peptide and anticoagulant drugs market growth.

Global Peptide and Anticoagulant Drugs Market

The peptide and anticoagulant drugs market is classified on the basis of type, Low molecular weight Heparin type, and application. On the basis of type, the market includes antibiotic, antifungal, hormonal, ace inhibitors, and other drugs. The hormonal segment is likely to lead the Indian peptide drugs market, in terms of revenue, owing to the increasing diabetes occurrence and rising global population. Based on low molecular weight Heparin type, the market is categorized into Dalteparin sodium, Fondaparinux, heparin sodium, and enoxaparin sodium. Enoxaparin sodium accounts for the largest share and dominates the market in terms of revenue. Based on application, the market includes gynecology, osteoporosis, infectious diseases, cancer, cardiology, diabetes, and others. Diabetes is dominating the market with the highest revenue share, due to the increasing number of diabetic patients across the globe.

North America dominates the peptide and anticoagulant drugs market with the largest revenue share, due to the growing inventions in clinical practice, rising access to cancer treatment, especially breast cancer, and cancer research. Europe held the second largest revenue share in 2018 of the peptide and anticoagulant drugs market, due to the increasing use of tobacco. The Asia Pacific peptide and anticoagulant drugs market will register the highest CAGR over the forecast time period, owing to the increasing incidences of cancer, metabolic disorders, and hepatitis, various developments witnessed in peptide synthesis technology, and growing demand for different peptide therapies in the region.

Some key players operating in the peptide and anticoagulant drugs market are Sun Pharmaceutical Industries, Baxter, HemmoPharma, Celsus, Wockhardt, AmbioPharm, Biofer, Bachem, Pfizer, Abbott Laboratories, Aspen, Eli Lilly, Takeda, Teva, Sanofi, and Novo Nordisk.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com